Hemoperfusion with Seraph-100 in septic patients removes pathogens and improves clinical outcomes

Hemoperfusion with Seraph-100 in septic patients removes pathogens and improves clinical outcomes

Abstract Hemoperfusion (HP) represents a treatment option for sepsis. This study evaluated Seraph-100 in septic patients admitted to the intensive care unit (ICU) after cardiac surgery due to infective endocarditis (IE). Thirteen septic patients were enrolled and treated by Seraph-100 hemoperfusion....

Full description

Saved in:
Bibliographic Details
Main Authors: Antonio Lacquaniti, Antonella Smeriglio, Fabrizio Ceresa, Susanna Campo, Daniele Caruso, Giuseppe Falliti, Erminia La Camera, Francesco Patané, Domenico Trombetta, Paolo Monardo
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:Scientific Reports
Subjects:
Seraph-100
Hemoperfusion
Sepsis
AKI
ICU stay
Online Access:https://doi.org/10.1038/s41598-025-01280-z
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Hemoperfusion (HP) represents a treatment option for sepsis. This study evaluated Seraph-100 in septic patients admitted to the intensive care unit (ICU) after cardiac surgery due to infective endocarditis (IE). Thirteen septic patients were enrolled and treated by Seraph-100 hemoperfusion. Fiftenne patients, not treated by HP, represented a control group. Pathogens were assessed before (T0) and after 4 h of HP treatment (T4). The difference between the two- quantification cycle (Cq) values (T0 and T4), namely ∆Cq at the polymerase chain reaction, was a surrogate marker of pathogen removal. The bacterial load decreased after Seraph-100 HP, with a mean ∆Cq values of 4.6 ± 2.4, as corroborated by conventional haemoculture’s results. Field Emission Scanning Electron Microscopy analyses confirm the Seraph’ adsorptive properties. Procalcitonin, C reactive protein and lactates significantly decreased, with a reduced ICU stay in the Seraph group. After HP, only 15% of patients had AKI requiring renal replacement therapy (RRT), significantly lower than that found in the control group (40%). The Seraph-100 HP induces a decrease of vasopressor doses, a hemodynamic stability and a reduction of AKI and RRT, improving the clinical course, reflected as a reduced ICU stay.
ISSN:2045-2322

Similar Items